These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 34768942)

  • 1. In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia.
    Hüttl M; Markova I; Miklankova D; Zapletalova I; Poruba M; Haluzik M; Vaněčkova I; Malinska H
    Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34768942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Empagliflozin Attenuates Non-Alcoholic Fatty Liver Disease (NAFLD) in High Fat Diet Fed ApoE
    Nasiri-Ansari N; Nikolopoulou C; Papoutsi K; Kyrou I; Mantzoros CS; Kyriakopoulos G; Chatzigeorgiou A; Kalotychou V; Randeva MS; Chatha K; Kontzoglou K; Kaltsas G; Papavassiliou AG; Randeva HS; Kassi E
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolic cardio- and reno-protective effects of empagliflozin in a prediabetic rat model.
    Huttl M; Markova I; Miklankova D; Oliyarnyk O; Trnovska J; Kucera J; Sedlacek R; Haluzik M; Malinska H
    J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33475091
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob
    Adingupu DD; Göpel SO; Grönros J; Behrendt M; Sotak M; Miliotis T; Dahlqvist U; Gan LM; Jönsson-Rylander AC
    Cardiovasc Diabetol; 2019 Feb; 18(1):16. PubMed ID: 30732594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress.
    Petito-da-Silva TI; Souza-Mello V; Barbosa-da-Silva S
    Mol Cell Endocrinol; 2019 Dec; 498():110539. PubMed ID: 31419466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metformin Affects Cardiac Arachidonic Acid Metabolism and Cardiac Lipid Metabolite Storage in a Prediabetic Rat Model.
    Miklankova D; Markova I; Hüttl M; Zapletalova I; Poruba M; Malinska H
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin lessened cardiac injury and reduced visceral adipocyte hypertrophy in prediabetic rats with metabolic syndrome.
    Kusaka H; Koibuchi N; Hasegawa Y; Ogawa H; Kim-Mitsuyama S
    Cardiovasc Diabetol; 2016 Nov; 15(1):157. PubMed ID: 27835975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress.
    Trnovska J; Svoboda P; Pelantova H; Kuzma M; Kratochvilova H; Kasperova BJ; Dvorakova I; Rosolova K; Malinska H; Huttl M; Markova I; Oliyarnyk O; Melcova M; Skop V; Mraz M; Stemberkova-Hubackova S; Haluzik M
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The SGLT2 inhibitor empagliflozin negatively regulates IL-17/IL-23 axis-mediated inflammatory responses in T2DM with NAFLD via the AMPK/mTOR/autophagy pathway.
    Meng Z; Liu X; Li T; Fang T; Cheng Y; Han L; Sun B; Chen L
    Int Immunopharmacol; 2021 May; 94():107492. PubMed ID: 33647823
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats.
    Jaikumkao K; Pongchaidecha A; Chueakula N; Thongnak LO; Wanchai K; Chatsudthipong V; Chattipakorn N; Lungkaphin A
    Diabetes Obes Metab; 2018 Nov; 20(11):2617-2626. PubMed ID: 29923295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Empagliflozin Improves Metabolic and Hepatic Outcomes in a Non-Diabetic Obese Biopsy-Proven Mouse Model of Advanced NASH.
    Perakakis N; Chrysafi P; Feigh M; Veidal SS; Mantzoros CS
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34199317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empagliflozin ameliorates symptoms of diabetes and renal tubular dysfunction in a rat model of diabetes with enlarged kidney (DEK).
    Domon A; Katayama K; Sato T; Tochigi Y; Tazaki H; Suzuki H
    PLoS One; 2021; 16(5):e0251135. PubMed ID: 33945582
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empagliflozin ameliorates liver fibrosis in NASH rat model via targeting hepatic NF-κB/SOX9/OPN signaling and osteocalcin level.
    Elseweidy MM; Ali AE; Hassanin SM; Mahmoud YK
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3449-3459. PubMed ID: 37962587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sweroside ameliorates NAFLD in high-fat diet induced obese mice through the regulation of lipid metabolism and inflammatory response.
    Yang Q; Shu F; Gong J; Ding P; Cheng R; Li J; Tong R; Ding L; Sun H; Huang W; Wang Z; Yang L
    J Ethnopharmacol; 2020 Jun; 255():112556. PubMed ID: 31926984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet.
    Xu L; Nagata N; Chen G; Nagashimada M; Zhuge F; Ni Y; Sakai Y; Kaneko S; Ota T
    BMJ Open Diabetes Res Care; 2019; 7(1):e000783. PubMed ID: 31749970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.
    Kolijn D; Pabel S; Tian Y; Lódi M; Herwig M; Carrizzo A; Zhazykbayeva S; Kovács Á; Fülöp GÁ; Falcão-Pires I; Reusch PH; Linthout SV; Papp Z; van Heerebeek L; Vecchione C; Maier LS; Ciccarelli M; Tschöpe C; Mügge A; Bagi Z; Sossalla S; Hamdani N
    Cardiovasc Res; 2021 Jan; 117(2):495-507. PubMed ID: 32396609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatoprotective effects of gemigliptin and empagliflozin in a murine model of diet-induced non-alcoholic fatty liver disease.
    Lee N; Heo YJ; Choi SE; Jeon JY; Han SJ; Kim DJ; Kang Y; Lee KW; Kim HJ
    Biochem Biophys Res Commun; 2022 Jan; 588():154-160. PubMed ID: 34971904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin alters lipid metabolism in the myocardium and liver in a prediabetes model with severe dyslipidemia.
    Miklankova D; Markova I; Hüttl M; Malinska H
    Front Pharmacol; 2024; 15():1393946. PubMed ID: 39027339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin not only improves hepatic injury and pancreatic endoplasmic reticulum stress, but also induces hepatic gluconeogenic enzymes expression in obese rats.
    Swe MT; Thongnak L; Jaikumkao K; Pongchaidecha A; Chatsudthipong V; Lungkaphin A
    Clin Sci (Lond); 2019 Dec; 133(23):2415-2430. PubMed ID: 31769484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats.
    Aragón-Herrera A; Feijóo-Bandín S; Otero Santiago M; Barral L; Campos-Toimil M; Gil-Longo J; Costa Pereira TM; García-Caballero T; Rodríguez-Segade S; Rodríguez J; Tarazón E; Roselló-Lletí E; Portolés M; Gualillo O; González-Juanatey JR; Lago F
    Biochem Pharmacol; 2019 Dec; 170():113677. PubMed ID: 31647926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.